keyword
MENU ▼
Read by QxMD icon Read
search

myelosuppression

keyword
https://www.readbyqxmd.com/read/29784961/sarcodon-imbricatus-polysaccharides-improve-mouse-hematopoietic-function-after-cyclophosphamide-induced-damage-via-g-csf-mediated-jak2-stat3-pathway
#1
Xue Wang, Qiubo Chu, Xue Jiang, Yue Yu, Libian Wang, Yaqi Cui, Jiahui Lu, Lirong Teng, Di Wang
Sarcodon imbricatus, a rare medicinal and edible fungus, has various pharmacological bioactivities. We investigated the effects of S. imbricatus polysaccharides (SIPS) on hematopoietic function and identified the underlying mechanisms using in vitro experiments with CHRF, K562, and bone marrow mononuclear cells (BMMNCs) and in vivo experiments with a mouse model of cyclophosphamide-induced hematopoietic dysfunction. We found that SIPS induced proliferation and differentiation of CHRF and K562 cells and upregulated the expression of hematopoietic-related proteins, including p90 ribosomal S6 kinases (RSK1p90), c-Myc, and ETS transcription factor, in the two cell lines...
May 21, 2018: Cell Death & Disease
https://www.readbyqxmd.com/read/29770217/analysis-of-adverse-events-of-renal-impairment-related-to-platinum-based-compounds-using-the-japanese-adverse-drug-event-report-database
#2
Misa Naganuma, Yumi Motooka, Sayaka Sasaoka, Haruna Hatahira, Shiori Hasegawa, Akiho Fukuda, Satoshi Nakao, Kazuyo Shimada, Koseki Hirade, Takayuki Mori, Tomoaki Yoshimura, Takeshi Kato, Mitsuhiro Nakamura
Objectives: Platinum compounds cause several adverse events, such as nephrotoxicity, gastrointestinal toxicity, myelosuppression, ototoxicity, and neurotoxicity. We evaluated the incidence of renal impairment as adverse events are related to the administration of platinum compounds using the Japanese Adverse Drug Event Report database. Methods: We analyzed adverse events associated with the use of platinum compounds reported from April 2004 to November 2016. The reporting odds ratio at 95% confidence interval was used to detect the signal for each renal impairment incidence...
2018: SAGE Open Medicine
https://www.readbyqxmd.com/read/29768957/comparison-of-the-incidence-of-febrile-neutropenia-in-obese-and-normal-weight-breast-cancer-patients-receiving-myelosuppressive-chemotherapy-and-prophylactic-pegfilgrastim
#3
Jennifer M Collins, Gini F Fleming, Trevor N Christ
Purpose Common breast cancer chemotherapy regimens are associated with a risk of febrile neutropenia, so prophylactic colony-stimulating factors are incorporated for high-risk patients. Filgrastim utilizes weight-based dosing; however, its sustained-release formulation utilizes fixed dosing. The purpose of this study is to determine whether obese breast cancer patients who receive pegfilgrastim are at increased risk of developing febrile neutropenia. Methods This study is a single-center, retrospective chart review...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29766239/-90-y-resin-microspheres-radioembolization-for-colon-cancer-liver-metastases-using-full-strength-contrast-material
#4
I Kurilova, R G H Beets-Tan, G A Ulaner, F E Boas, E N Petre, H Yarmohammadi, E Ziv, A R Deipolyi, L A Brody, M Gonen, Constantinos T Sofocleous
OBJECTIVES: To assess safety and efficacy of 90 Y resin microspheres administration using undiluted non-ionic contrast material (UDCM) {100% Omnipaque-300 (Iohexol)} in both the "B" and "D" lines. MATERIALS AND METHODS: We reviewed all colorectal cancer liver metastases patients treated with 90 Y resin microspheres radioembolization (RAE) from 2009 to 2017. As of April 2013, two experienced operators started using UDCM (study group) instead of standard sandwich infusion (control group)...
May 15, 2018: Cardiovascular and Interventional Radiology
https://www.readbyqxmd.com/read/29755706/infectious-risks-and-complications-in-adult-leukemic-patients-receiving-blinatumomab
#5
Wonhee So, Shuchi Pandya, Rod Quilitz, Bijal Shah, John N Greene
Background: Blinatumomab is an anti-CD19 immunotherapy approved for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with significantly increased survival rate. While blinatumomab showed lower rates of infection, neutropenia and mucosal barrier injury versus chemotherapy, its infection risks are not well described. Methods: All patients who received blinatumomab for ≥ seven days at an academic cancer center from May 2015 to April 2017 were included...
2018: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/29753159/defining-incidence-and-risk-factors-for-catheter-associated-bloodstream-infections-in-an-outpatient-adult-hematopoietic-cell-transplant-program
#6
Marissa K McDonald, Kathryn A Culos, Katie S Gatwood, Caleb Prow, Heidi Chen, Bipin N Savani, Michael Byrne, Adetola A Kassim, Brian G Engelhardt, Madan Jagasia, Gowri Satyanarayana
BACKGROUND: Allogeneic hematopoietic cell transplant (HCT) patients are at an increased risk of developing central line-associated bloodstream infections (CLABSIs) due to prolonged periods of myelosuppression, immunosuppression, and indwelling catheter days. CLABSIs are among the most serious complications in HCT recipients and can lead to prolonged hospitalizations, intensive care unit (ICU) admissions, lengthy antimicrobial therapies, and increased mortality. There is a lack of data regarding the incidence and risk factors associated with the development of CLABSIs in the HCT population undergoing outpatient transplantation...
May 9, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29747541/risk-benefit-of-dexrazoxane-for-preventing-anthracycline-related-cardiotoxicity-re-evaluating-the-european-labeling
#7
Peter Reichardt, Marie-Dominique Tabone, Jaume Mora, Bruce Morland, Robin L Jones
Dexrazoxane can prevent anthracycline-associated cardiotoxicity. However, in 2011, its use in children was contraindicated by the EMA over concerns of increased risk of infection, myelosuppression and second primary malignancies, and because its efficacy in children had not then been established. We review here the evidence published since 2011, which confirms that dexrazoxane is an effective cardioprotectant in children and adolescents, is not associated with an increased risk of second primary malignancies or excess early or late mortality and does not impair chemotherapy efficacy...
May 11, 2018: Future Oncology
https://www.readbyqxmd.com/read/29746444/role-of-letermovir-for-prevention-of-cytomegalovirus-infection-after-allogeneic-haematopoietic-stem-cell-transplantation
#8
Raymund R Razonable
PURPOSE OF REVIEW: Cytomegalovirus (CMV) infection is a common opportunistic infection after allogeneic haematopoietic stem cell transplantation (HSCT). CMV surveillance-preemptive therapy is the current preferred approach for preventing CMV disease after HSCT. In contrast, antiviral prophylaxis is not commonly used due to myelosuppressive effects of valganciclovir. In this article, the role of the newly approved antiviral compound, letermovir, is reviewed. RECENT FINDINGS: Letermovir inhibits CMV by interfering viral terminase complex...
May 8, 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29732532/pathogenesis-diagnosis-and-treatment-of-anaemia-in-immune-mediated-gastrointestinal-disorders
#9
REVIEW
Gaetano Bergamaschi, Antonio Di Sabatino, Gino R Corazza
Immune-mediated disorders affecting the gastrointestinal (GI) tract may compromise GI integrity, interfere with the absorption of nutrients and cause bleeding and inflammation. All these features contribute to the pathogenesis of anaemia, the most prevalent extra-intestinal manifestation of immune-mediated GI disorders. Anaemia is most commonly due to iron deficiency and/or inflammation, but vitamin deficiencies and, more infrequently, autoimmune haemolysis or drug-induced myelosuppression can be involved. Here we address several issues related to the differential diagnosis and treatment of anaemia in immune-mediated GI disorders, giving particular relevance to the problem of iron deficiency anaemia associated with inflammation...
May 6, 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29730918/-a-multicenter-large-sample-randomized-clinical-trial-on-improving-the-median-survival-time-of-advanced-non-small-cell-lung-cancer-by-combination-of-ginseng-rg3-and-chemotherapy
#10
Y Zhang, X Q Wang, H Liu, J Liu, W Hou, H S Lin
Objective: To observe the efficacy of the combination of chemotherapy and Ginseng Rg3 on advanced non-small cell lung cancer(NSCLC). Methods: In the multi-center, large-sample, randomized, double blind trial, 414 patients with Ⅲ-Ⅳ NSCLC were enrolled.199 were in the experimental group and 215 the control group. The patients in the experimental group were treated with the standard first-line chemotherapy combined with Ginseng Rg3. The patients in the control group were treated with the same chemotherapy combined with placebo...
April 23, 2018: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
https://www.readbyqxmd.com/read/29727524/use-of-charcoal-hemoperfusion-and-hemodialysis-in-the-treatment-of-methotrexate-toxicosis-in-a-dog
#11
Mariana Pardo, Travis Lanaux, Rachel Davy, Carsten Bandt
OBJECTIVE: To describe the successful use of charcoal hemoperfusion (HP) and hemodialysis (HD) in a dog in the treatment of methotrexate (MTX) toxicosis. CASE SUMMARY: An American Pit Bull Terrier accidentally ingested 56.8 mg/m2 of MTX. The patient's initial serum MTX concentration was 0.11 μmol/L. At this dosage, myelosuppression and gastrointestinal epithelial necrosis have been reported. Charcoal HP and HD in series were used to enhance elimination of MTX...
May 2018: Journal of Veterinary Emergency and Critical Care
https://www.readbyqxmd.com/read/29724902/phase-i-trial-of-plerixafor-combined-with-decitabine-in-newly-diagnosed-older-patients-with-acute-myeloid-leukemia
#12
Gail J Roboz, Ellen K Ritchie, Yulia Dault, Linda Lam, Danielle C Marshall, Nicole M Cruz, Hsiao-Ting C Hsu, Duane C Hassane, Paul J Christos, Cindy Ippoliti, Joseph M Scandura, Monica L Guzman
Acute myeloid leukemia carries a dismal prognosis in older patients. The objective of this study was to investigate the safety and efficacy of decitabine combined with the CXCR4 antagonist plerixafor in newly diagnosed older patients with acute myeloid leukemia and to evaluate the effects of plerixafor on leukemia stem cells. Patients were treated with monthly cycles of decitabine 20 mg/m2 days 1-10 and escalating doses of plerixafor (320-810 mcg/kg) days 1-5. Sixty-nine patients were treated, with overall response rate 43%...
May 3, 2018: Haematologica
https://www.readbyqxmd.com/read/29723397/early-results-of-lower-dose-dasatinib-50-mg-daily-as-frontline-therapy-for-newly-diagnosed-chronic-phase-chronic-myeloid-leukemia
#13
Kiran Naqvi, Elias Jabbour, Jeffrey Skinner, Musa Yilmaz, Alessandra Ferrajoli, Prithviraj Bose, Philip Thompson, Yesid Alvarado, Nitin Jain, Koichi Takahashi, Jan Burger, Zeev Estrov, Gautam Borthakur, Naveen Pemmaraju, Shilpa Paul, Jorge Cortes, Hagop M Kantarjian
BACKGROUND: Dasatinib is a potent BCR-ABL1 and Src family tyrosine kinase inhibitor. It is approved at a dose of 100 mg orally daily for the treatment of chronic myeloid leukemia in chronic phase (CML-CP). This dose schedule is associated with myelosuppression and pleural effusions. Anecdotal data suggest that lower doses may be as effective and less toxic. The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP...
May 3, 2018: Cancer
https://www.readbyqxmd.com/read/29722659/tolerability-of-adxs11-001-lm-llo-listeria-based-immunotherapy-with-mitomycin-fluorouracil-and-radiation-for-anal-cancer
#14
Howard Safran, Kara-Lynne Leonard, Kimberly Perez, Matthew Vrees, Adam Klipfel, Steven Schechter, Nicklas Oldenburg, Leslie Roth, Nishit Shah, Kayla Rosati, Lakshmi Rajdev, Kalyan Mantripragada, Iris Y Sheng, Peter Barth, Thomas A DiPetrillo
PURPOSE: To obtain safety and preliminary efficacy data of the combination of ADXS11-001, live attenuated Listeria monocytogenes bacterium, with mitomycin, 5-fluorouracil (5-FU), and intensity modulated radiation therapy in locally advanced anal cancer. PATIENTS AND METHODS: Eligibility included patients with previously untreated, nonmetastatic anal cancer with a primary tumor >4 cm or node-positive disease. Patients received 2 cycles of mitomycin and 5-FU concurrent with 54...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29720126/optimal-predictor-for-6-mercaptopurine-intolerance-in-chinese-children-with-acute-lymphoblastic-leukemia-nudt15-tpmt-or-itpa-genetic-variants
#15
Hong Zhou, Lei Li, Peng Yang, Lin Yang, Jin E Zheng, Ying Zhou, Yong Han
BACKGROUND: 6-mercaptopurine (6-MP) contributes substantially to remarkable improvement in the survival of childhood acute lymphoblastic leukemia (ALL) patients. However, 6-MP also has dose-limiting toxicities, particularly life-threatening myelosuppression, due to genetic polymorphisms in enzymes that metabolize 6-MP. Promising biomarkers for predicting 6-MP-induced leukopenia is still unclear in Chinese population. Here, we evaluated the associations of NUDT15, TPMT and ITPA genotypes with 6-MP intolerance in our cohort of childhood ALL patients...
May 2, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29715082/efficacy-of-asparaginase-erwinia-chrysanthemi-with-and-without-temozolomide-against-glioma-cells-and-intracranial-mouse-medulloblastoma
#16
Valentina Sanghez, Mengqing Chen, Shan Li, Tsui-Fen Chou, Michelina Iacovino, Henry J Lin, Joseph L Lasky, Eduard H Panosyan
BACKGROUND: Anti-metabolites are less-myelosuppressive than DNA-damaging anticancer drugs and may be useful against brain tumors. MATERIALS AND METHODS: We evaluated the asparagine/glutamine-deaminating agent Erwinaze with/without temozolomide against brain tumor cells and mouse medulloblastomas. RESULTS: Erwinaze treatment of cell lines and neurospheres led to dose-dependent reductions of cells (reversible by L-glutamine), with half maximal inhibitory concentrations (IC50 s) of 0...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29704867/azathioprine-induced-alopecia-and-leukopenia-associated-with-nudt15-polymorphisms
#17
H Nomura, Y Kurihara, M Saito, A Fukushima, Y Shintani, R Shiiyama, S Toshima, A Kamata, J Yamagami, T Funakoshi, K Kameyama, M Amagai, A Kubo, N Umegaki-Arao
Azathioprine (AZA), a widely used immunosuppressant, can induce cytotoxic effects including myelosuppression and alopecia.1 Recent studies revealed that polymorphisms of NUDT15 are associated with thiopurine-induced alopecia and leukopenia.2-5 The frequency of NUDT15 polymorphisms in East and South Asians is high (22.6% and 13.6%, respectively).5 Thus, adverse event management during AZA treatment is essential for Asian populations with these polymorphisms. This article is protected by copyright. All rights reserved...
April 28, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29695770/systemic-immune-response-induced-by-oxaliplatin-based-neoadjuvant-therapy-favours-survival-without-metastatic-progression-in-high-risk-rectal-cancer
#18
Erta Kalanxhi, Sebastian Meltzer, Jakob Vasehus Schou, Finn Ole Larsen, Svein Dueland, Kjersti Flatmark, Benny Vittrup Jensen, Knut Håkon Hole, Therese Seierstad, Kathrine Røe Redalen, Dorte Lisbet Nielsen, Anne Hansen Ree
BACKGROUND: Systemic failure remains a challenge in rectal cancer. We investigated the possible systemic anti-tumour immune activity invoked within oxaliplatin-based neoadjuvant therapy. METHODS: In two high-risk patient cohorts, we assessed the circulating levels of the fms-like tyrosine kinase 3 ligand (Flt3L), a factor reflecting both therapy-induced myelosuppression and activation of tumour antigen-presenting dendritic cells, at baseline and following induction chemotherapy and sequential chemoradiotherapy, both modalities containing oxaliplatin...
April 26, 2018: British Journal of Cancer
https://www.readbyqxmd.com/read/29692632/thrombocytopenia-and-bleeding-in-myelosuppressed-transfusion-dependent-patients-a-simulation-study-exploring-underlying-mechanisms
#19
Rutger A Middelburg, Jean-Louis H Kerkhoffs, Johanna G van der Bom
Background: Hematology-oncology patients often become severely thrombocytopenic and receive prophylactic platelet transfusions when their platelet count drops below 10×109 platelets/L. This so-called "platelet count trigger" of 10×109 platelets/L is recommended because currently available evidence suggests this is the critical concentration at which bleeding risk starts to increase. Yet, exposure time and lag time may have biased the results of studies on the association between platelet counts and bleeding risks...
2018: Clinical Epidemiology
https://www.readbyqxmd.com/read/29684456/radioprotective-effect-of-orally-administered-beta-d-glucan-derived-from-saccharomyces-cerevisiae
#20
Fang Liu, Zhuanzi Wang, Jia Liu, Wenjian Li
The present study was to evaluate the in vivo radioprotective effect of oral administration of Saccharomyces cerevisiae-derived-beta-d-glucan (S. cerevisiae-BG) and to investigate the protective mechanism. The results demonstrated that oral pretreatment with 350 mg/kg S. cerevisiae-BG once daily for 14 consecutive days significantly increased the survival rate of mice from 6 Gy X-rays irradiation. At the 30th day after irradiation, cellularity and the percentage of hematopoietic stem/progenitor cells in bone marrow (BM) of surviving mice were increased by S...
April 20, 2018: International Journal of Biological Macromolecules
keyword
keyword
97609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"